# DTGM Fusion Protein in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia

> **NCT00003840** · PHASE1,PHASE2 · COMPLETED · sponsor: **Wake Forest University Health Sciences**

## Conditions studied

- Leukemia

## Interventions

- **BIOLOGICAL:** DTGM fusion protein

## Key facts

- **NCT ID:** NCT00003840
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-10
- **Primary completion:** 2002-09
- **Final completion:** 2005-07
- **Target enrollment:** — (—)
- **Last updated:** 2017-01-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003840

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003840, "DTGM Fusion Protein in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00003840. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*